Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095181 Target Snapshot

Opioid receptors; mu/kappa/delta · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
285Compounds
257Assays
7Approved Drugs
172.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Opioid receptors; mu/kappa/delta shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P41145. Start with pain, then reuse UniProt P41145 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with pain, then reuse UniProt P41145 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 10 linked drugs
Open source guide
Disease program
pain

Opioid receptors; mu/kappa/delta shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 10 linked drugs remain visible in the same block.

Start review with pain because it currently carries approved-linked support. Linked drugs include CEBRANOPADOL, CODEINE PHOSPHATE, CODEINE SULFATE, DEXTROMORAMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 10 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Opioid receptors; mu/kappa/delta as ChEMBL target CHEMBL2095181, mapped to UniProt P41145. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Opioid receptors; mu/kappa/delta
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2095181
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P41145
Kappa-type opioid receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Opioid receptors; mu/kappa/delta is the right protein anchor across sources, using UniProt P41145 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why pain is currently framed as approved-linked support. It currently carries 10 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameOpioid receptors; mu/kappa/delta
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP41145
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelKappa-type opioid receptor
UniProt AccessionP41145
Component TypeProtein
Sequence Length380 aa

Kappa-type opioid receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Opioid receptors; mu/kappa/delta, mapped to UniProt P41145. ChEMBL maps the protein component as Kappa-type opioid receptor. Sequence length is 380 aa.

Mapped IDP41145
Review nameOpioid receptors; mu/kappa/delta
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Opioid receptors; mu/kappa/delta shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
pain
10 linked drugs · 10 direct · 10 efficacy
Linked drugCEBRANOPADOL
Linked drugCODEINE PHOSPHATE
Linked drugCODEINE SULFATE
Linked drugDEXTROMORAMIDE
Approved-linked Approved
drug dependence
5 linked drugs · 5 direct · 5 efficacy
Linked drugCEBRANOPADOL
Linked drugCODEINE PHOSPHATE
Linked drugCODEINE SULFATE
Linked drugHYDROCODONE BITARTRATE
Approved-linked Approved
opioid dependence
5 linked drugs · 5 direct · 5 efficacy
Linked drugNALBUPHINE HYDROCHLORIDE
Linked drugNALOXONE HYDROCHLORIDE
Linked drugNALOXONE HYDROCHLORIDE DIHYDRATE
Linked drugNALTREXONE
Approved-linked Approved
pain
3 linked drugs · 3 direct · 3 efficacy
Linked drugBENZHYDROCODONE HYDROCHLORIDE
Linked drugHYDROCODONE BITARTRATE
Linked drugOXYMORPHONE HYDROCHLORIDE
Approved-linked Approved
alcohol dependence
2 linked drugs · 2 direct · 2 efficacy
Linked drugNALTREXONE
Linked drugONDELOPRAN
Approved-linked Approved
migraine disorder
2 linked drugs · 2 direct · 2 efficacy
Linked drugCODEINE PHOSPHATE
Linked drugNALTREXONE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with pain because it currently carries approved-linked support. Linked drugs include CEBRANOPADOL, CODEINE PHOSPHATE, CODEINE SULFATE, DEXTROMORAMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasepain
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
4
Phase II
Assay Mix

Activity Type Distribution

IC50169.0
KI3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL56347 10.15 IC50 0.07 Preclinical
CHEMBL384584 9.66 IC50 0.22 Preclinical
CHEMBL415330 9.62 IC50 0.24 Preclinical
CHEMBL172293 9.55 IC50 0.28 Preclinical
CHEMBL140050 9.52 IC50 0.3 Clinical
CHEMBL350384 9.3 IC50 0.5 Clinical
CHEMBL1201149 9.26 IC50 0.55 Approved
CHEMBL170858 9.23 IC50 0.59 Preclinical
CHEMBL278086 9.22 IC50 0.6 Preclinical
CHEMBL3249714 9.15 IC50 0.7 Preclinical
Distribution

pChEMBL Value Distribution

4
5.0
8
5.5
6
6.0
14
6.5
22
7.0
43
7.5
26
8.0
21
8.5
8
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

NALTREXONE HYDROCHLORIDE
CHEMBL1201149
Approved 1984
Properties Compare Identifier
NALTREXONE
CHEMBL19019
Approved 1984
Properties Compare Identifier
MORPHINE
CHEMBL70
Approved 1984
Properties Compare Identifier
NALOXONE
CHEMBL80
Approved 1971
Properties Compare Identifier
NALOXONE HYDROCHLORIDE
CHEMBL1718
Approved 1971
Properties Compare Identifier
OXYMORPHONE
CHEMBL963
Approved 1959
Properties Compare Identifier
MEPERIDINE
CHEMBL607
Approved 1942
Properties Compare Identifier
Assay Landscape

Assay Landscape

257
Total Assays
101
Tested Compounds
2
Assay Types
Binding — 194 assays, 101 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 124 27 6.9
assay format 31 38 7.8
cell membrane format 22 20 7.7
tissue-based format 17 16 7.7
Functional — 63 assays, 41 compounds
BAO Format Assays Compounds Avg pChEMBL
tissue-based format 37 36 7.9
assay format 26 5 7.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine